Topic update: this appraisal has not been defined as therapeutically critical. The appraisal will therefore be paused. At this stage, we are unable to provide alternative timelines as to when the appraisal may be re-started but we will provide an update when this information is available.
 
Status Schedule affected by COVID-19
Process CDF Review
ID number 1572

Project Team

Project lead Louise Jafferally

Email enquiries

Evidence Review Group / Assessment Group Liverpool Reviews and Implementation Group, University of Liverpool

Consultees

Companies sponsors Bristol-Myers Squibb (nivolumab)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Roy Castle Lung Cancer Foundation
Professional groups Association of Cancer Physicians
  British Thoracic Society
  Cancer Research UK
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists

Commentators

Comparator companies Lilly UK (pemetrexed, gemcitabine) (confidentiality agreement signed, participating)
  Pfizer (cisplatin, crizotinib) (confidentiality agreement signed, participating)
  Roche Products (erlotinib) (confidentiality agreement signed, participating)
  Accord Healthcare (carboplatin, cisplatin, docetaxel, gemcitabine, paclitaxel) (confidentiality agreement not signed, not participating)
  Actavis UK (docetaxel, gemcitabine, paclitaxel, vinorelbine) (confidentiality agreement not signed, not participating)
  Boehringer Ingelheim (nintedanib, afatinib) (confidentiality agreement not signed, not participating)
  Hospira UK (carboplatin, cisplatin, docetaxel, gemcitabine, paclitaxel) (confidentiality agreement not signed, not participating)
  Medac UK (docetaxel, gemcitabine, paclitaxel, vinorelbine) (confidentiality agreement not signed, not participating)
  Novartis Pharmaceuticals (certitinib) (confidentiality agreement not signed, not participating)
  Pierre Fabre (vinorelbine) (confidentiality agreement not signed, not participating)
  Sanofi (docetaxel) (confidentiality agreement not signed, not participating)
  Sun Pharmaceuticals (carboplatin, gemcitabine) (confidentiality agreement not signed, not participating)
  Teva UK (docetaxel) (confidentiality agreement not signed, not participating)
  Wockhardt UK (vinorelbine) (confidentiality agreement not signed, not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
05 May 2020 Schedule affected by COVID-19. Topic update: this appraisal has not been defined as therapeutically critical. The appraisal will therefore be paused. At this stage, we are unable to provide alternative timelines as to when the appraisal may be re-started but we will provide an update when this information is available.
07 April 2020 Topic update: this appraisal has not been defined as therapeutically critical (please follow the link titled rapid guidelines and evidence summaries within the yellow banner at the top of the page for information on recent changes to the way we work). The appraisal will therefore be paused. At this stage, we are unable to provide alternative timelines as to when the appraisal may be re-started but we will provide updates as and when this information becomes clear.
18 March 2020 Committee meeting: 1
06 December 2019 Appraisal in progress.
03 September 2019 This appraisal topic is paused to allow the company to provide updated submission documentation. The appraisal will be rescheduled into the work programme and the updated appraisal timelines will be communicated, once known.
19 July 2019 Invitation to participate
11 July 2019 In progress. Start date of invitation to participate

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance